Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RVT-503 (also known as DMVT-503) is an investigational small molecule inhibitor of diacylglycerol O-acyltransferase 1 (DGAT1) that was developed by Dermavant Sciences, a subsidiary of Roivant Sciences. The drug was designed as a topical treatment for acne vulgaris, targeting the enzymatic pathway responsible for the final step of triglyceride synthesis. By inhibiting DGAT1 in the skin, RVT-503 aimed to reduce sebum production and modify its composition, thereby addressing one of the primary drivers of acne pathogenesis. In 2022, Roivant Sciences announced the discontinuation of the RVT-503 program as part of a strategic pipeline reprioritization to focus resources on the commercial launch of tapinarof (VTAMA) and other late-stage clinical assets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RVT-503.